Bourlon MT, Velazquez HE, Hinojosa J, et al. - The present study was intended to evaluate the potential induction of premature immunosenescence in testicular cancer survivors (TCS) exposed to chemotherapy. Researchers compared a case-control exploratory study of TCS treated with chemotherapy (≥ 3 BEP (bleomycin, etoposide, and cisplatin) cycles, disease-free ≥ 3 months) with age-matched healthy controls. Peripheral blood mononuclear cells were isolated, and they examined lymphocyte subpopulations by flow cytometry. This study enrolled 16 cases and 16 controls. TCS exhibited elevated expression of CDKN2A/p16^INK4alymphocyte phenotype that has been associated with immunosenescence in this exploratory study. Future trials are required to characterize the clinical implications of these alterations in TCS.